Founder, OneVentures
| Role | Organisation | Sources |
|---|---|---|
| Chairman (former) | Hatchtech | GBS Ventures |
| Founder | OneVentures | OneVentures team page |
| Partner and Managing Director (former) · Founder | OneVentures | Startup Daily (29 Aug 2025), Startup Daily (26 Aug 2025), Startup Daily (17 Jan 2024), Brandon Capital portfolio, Brandon BioCatalyst portfolio, einpresswire.com, OneVentures team page |
| Director (former) | Vaxxas | Startup Daily (29 Aug 2025), SmartCompany, Startup Daily (26 Aug 2025), Business News Australia, sprim.com |
Stories naming Dr Paul Kelly. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Weekly roundup detailing five Australian raises: Vaxxas' Series D plus debt facility amid executive changes, Skutopia's growth round, Send Payments' backing and CEO change, Apate.ai's seed, and Coursebox's seed.
Also Startup Daily·SmartCompany·Australian FinTech·Dealroom·Startup Daily
Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.
Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
The renewable energy agency commits grant funding to two solar projects: forecasting software at PV Lighthouse and robot automation of solar farm construction at Built Robotics.
Manufacturing sector roundup: Whyalla steelworks resumes production, Maggie Beer Holdings' chief executive to depart, ReNu Energy secures hydrogen funding, Defence names grant recipients, Orthocell gains Canadian approval, and AEA appoints its advisory board.
Prota Therapeutics, a Melbourne biotech, has secured $32 million in equity and debt ahead of a Phase 3 trial of its peanut allergy therapy, with Singapore's SPRIM Global Investments leading the round.
Also SmartCompany·SmartCompany·SmartCompany·Business News Australia·Forbes Australia
Perth fintech PictureWealth has bought out licence holders Futuro Financial Services and Insight Investment Services from majority owner Highfield Group, with existing leaders staying on as chairman Dennis Bashford plans succession.
Vaxxas completed a US$23 million (A$34 million) financing led by OneVentures and UniQuest to advance its needle-free vaccine clinical programs, including a COVID-19 candidate, with board members, management and individual investors also participating.
Also OneVentures portfolio·Brandon Capital portfolio·@AuManufacturing·SmartCompany·Techboard·@AuManufacturing
Diagnostics company Clinical Genomics closed a $15m Series A led by Sydney VC OneVentures to commercialise its blood test for monitoring bowel cancer recurrence; OneVentures partner Dr Paul Kelly joins its board.
Australian pharmaceutical developer Hatchtech appoints Tim Waugh, a former Roche divisional vice president, as chief executive officer to lead development and commercialisation of its head lice treatment DeOvo and establish a United States presence.